NEW YORK (GenomeWeb News) – Oncodesign today announced an agreement with Eisai to assess the use of Halaven Injection (eribulin) in earlier line treatment of metastatic breast cancer. 

Oncodesign will conduct in vivo pharmacology studies and Eisai will perform gene expression profiling analysis using Oncodesign's patient-derived xenograft models to evaluate Eisai's Halaven, a non-taxane microtubule dynamics inhibitor. Oncodesign could receive up to €1.25 million ($1.56 million) in revenue for its contributions and has received €900,000 to date, it said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.